1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group.

Slides:



Advertisements
Similar presentations
Elicitation methods Health care demands exceed resource supply Therefore, rationing is inevitable Many ways by which we can ration health care One is economic.
Advertisements

Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
Implementing NICE guidance
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
BACKGROUND AND AIM Website: Challenges in conducting a systematic review of the diagnostic accuracy of genetic tests: an example.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
Decision Analysis. What is decision analysis? Based on expected utility theory Based on expected utility theory Used in conditions of uncertainty Used.
Balancing efficiency and equity in formal economic evaluation of health care. Erik Nord, Senior Researcher, Norwegian Institute of Public Health, Professor.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Utility Assessment HINF Medical Methodologies Session 4.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. February 25, 2009.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
Journal Club Alcohol and Health: Current Evidence March-April 2006.
A RECIPE FOR INCOHERENCE: AVERAGING TIME-TRADEOFF OR STANDARD-GAMBLE UTILITIES ACROSS HEALTH ATTRIBUTES Gordon B. Hazen, IEMS Department, Northwestern.
Estimating utilities from individual preference data Some introductory remarks by Tony O’Hagan.
Utilising rank and DCE data to value health status on the ‘QALY’ scale using conventional and Bayesian methods John Brazier and Theresa Cain with Aki Tsuchiya.
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
DISCUSSION Alex Sutton Centre for Biostatistics & Genetic Epidemiology, University of Leicester.
Measuring and valuing health outcome Montarat Thavorncharoensap, Ph.D. 1: Faculty of Pharmacy, Mahidol University 2. HITAP, Thailand.
1. Critical appraisal and qualitative research: exploring sensitivity analysis Angela Harden Methods for Research Synthesis Node, ESRC National Centre.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Introduction to Effectiveness, Patient Preferences and Utilities Patsi Sinnott, PT, PhD, MPH HERC Economics Course May 6, 2009.
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
Overview of the EQ-5D Purpose and origins of the descriptive system.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Rescuing Clinical Trial Data For Economic Evaluation
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
How can societal concerns for fairness be integrated in economic evaluations of health programs? Erik Nord, PhD, Senior Researcher, Norwegian Institute.
Measuring Health Outcomes
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2013.
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
HERU is supported by the Chief Scientist Office of the Scottish Executive Health Department. The author accepts full responsibility for this talk. Economic.
1 QALY, Burden of Disease and Budget Impact  Jan J.V. Busschbach, Ph.D.  Erasmus MC, Rotterdam, The Netherlands  
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
What is a QALY?. QALY’s Person’s length of life weighted by a valuation of their health-related quality of life.  Quantity (T)  Quality (U) Equation:
Validation / citations. Validation u Expert review of model structure u Expert review of basic code implementation u Reproduce original inputs u Correctly.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Patsi Sinnott, PT, PhD, MPH HERC Economics Course April 7, 2010 Introduction to Effectiveness, Patient Preferences and Utilities.
{ Challenges in cost-utility analysis in the critical care setting Ville Pettilä MD, PhD, A/P Helsinki University Hospital VP SFAI- veckan.
Vanderbilt Sports Medicine Chapter 5: Therapy, Part 2 Thomas F. Byars Evidence-Based Medicine How to Practice and Teach EBM.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
Make Nutrition Services Count: Cost-Effectiveness Research & Outcomes Research.
1 Scale recalibration effects in dementia patients and their proxies Sander Arons Dept. of Epidemiology, Biostatistics and HTA Radboud University Nijmegen.
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
Healthy ageing in relation to chronic pain in the EU Jos Kleijnen and Nigel Armstrong Kleijnen Systematic Reviews Ltd, York, UK.
Tertiary Education Systems and Labour Markets Report prepared for the OECD Stephen Machin* and Sandra McNally** 1 December 2006 *Centre for Economic Performance,
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
EQ-5D and SF-36 Quality of Life Measures in Systemic Lupus Erythematosus: Comparisons with RA, Non-Inflammatory Disorders (NIRD), and Fibromyalgia (FM)
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*
Cost-effectiveness of pneumococcal vaccination for older people: a study in five western European countries Ament A, Baltussen R, Duru G, Rigaud-Bully.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
LSE Summit Rethinking regulation and value assessment of medical technologies: challenges and opportunities Valentina Prevolnik Rupel, PhD Institute for.
1 VAS, SG, TTO and PTO An Interactive Introduction.
1 Study on the Coverage of Chronic Diseases in Social and Health Protection Systems: A Comparative Analysis of Trends in Developed Countries and in the.
The valuation of disease-specific questionnaires for QALY analysis
Are values cultural determined…..
Stephen Machin* and Sandra McNally** 1 December 2006
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group

2 First international comparisons in 1988 with EQ-6D and VAS

3 Does TTO differs in Western Europe ?

4 Replication TTO in the UK

5 Do European values differs to the rest of the world ?

6 Does VAS differs across nations?

7 Positive TTO values differ little

8 Negative TTO values seem to matter

9 New evidence  UK  Scottish population is tougher  Only publish in main report  US  Black, Hispanic differ  Yet to be published  Publication bias  Difficulty disentangle Test retest reliability Cultural effect  What should be the consequence of cultural difference?

10 Conclusions  Patient values include coping  High values  Cultural differences exists  Especially in (negative) TTO values  Not yet clear what the consequences are Or should be…

11 Little difference between Cost/Life Year and Cost/QALY Richard Chapman et al, 2004, Health Economics

12 Difference in QALYs makes little difference in outcome  Richard Chapman et al, 2004  “In a sizable fraction of cost-utility analyses, quality adjusting did not substantially alter the estimated cost-effectiveness of an intervention, suggesting that sensitivity analyses using ad hoc adjustments or 'off-the-shelf' utility weights may be sufficient for many analyses.”  “The collection of preference weight data should […] should only be under-taken if the value of this information is likely to be greater than the cost of obtaining it.”

13 QALYs make a difference when:  Chronic disease  Palliative  Long term negative consequences

14 Person Trade-Off  Values between patients  Not ‘within’ a patient like SG, TTO and VAS  Better equipped for QALY?  V(Q) = 1 - (A / B)  For instance:  V(Q) = 1 - (100/300)  V(Q) =  V(Q) = 0.67 ?? persons 1 year free from disease Q 100 persons additionally 1 healthy year

15 PTO gives extreme low values

16 PTO and it’s psychometrics  Paul Kind:  If we look at TTO and PTO...  we see that one of them is wrong  If we look at PTO alone...  We still see that one of them is wrong... PTO is not a quick fix